News

The trial will target patients with advanced undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS) after second-line treatment. The design of this single-arm trial aims to accelerate the registration process for the therapy. The company's decision to focus on these two rare soft tissue sarcoma subtypes reflects its strategic positioning in the field of tumor immunotherapy. By targeting advanced patient populations who have undergone first-line treatment, Iovance hopes to open new avenues for the application of its cell therapy in these hard-to-treat cancers. The timing of the trial is based on a comprehensive assessment of the company's R&D pipeline progress. The choice of the second quarter of 2026 takes into account both the maturity of preclinical research and the time required for regulatory communications. The adoption of a single-arm trial design is expected to accelerate the accessibility of potential therapies while ensuring scientific rigor.

This outlook reflects the group’s interim challenges during its business transformation process. Although specific figures were not disclosed in detail, the term “slightly below” suggests that its profitability may be affected by rising operating costs or a slowdown in certain market growth. Notably, as a key player in the industrial services sector, fluctuations in Harsco’s dual business lines are often regarded as a leading indicator of the industry’s overall prosperity. Analysts point out that the move to lower the midpoint of the 2026 EBITDA guidance may prompt investors to reassess Enviri’s medium- and long-term strategic execution efficiency. However, the company has not revised its 2025 targets, indicating that management remains confident in its near-term operating conditions.

This groundbreaking development marks a key step forward for TIL cell therapy in the treatment of solid tumors, bringing new hope for patients with soft tissue sarcoma.